Crosslink Therapeutics Inc. — SEC Form D Filing
Crosslink Therapeutics Inc. filed an SEC Form D on October 20, 2026, reporting $5.50M raised in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- October 20, 2026
- Amount reported
- $5.50M
- Round stage
- Seed
- Industry
- Biotechnology
- Website
- https://www.xlinktx.com/
What the company does
Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Solid tumors release elevated levels of extracellular adenosine triphosphate (eATP) compared to normal tissue, helping the cancer develop and grow.
Solution
Crosslink has engineered a modular biologic domain that uses elevated eATP to conditionally assemble therapeutics directly within tumors, currently focusing on applications in antibody drug conjugates and radioligand therapies to improve tumor-specific targeting.
Why now
The therapeutic window of potent modalities like ADCs and radioligands remains constrained by systemic toxicity, driving urgency for conditional, tumor-microenvironment-activated platforms.
Verdict
This cleared because the narrative hitched itself directly to urgent toxicity bottlenecks in booming ADC and radioligand deal markets, not because tumor-microenvironment targeting is an uncrowded space. Investors wrote a $5.5M check betting that eATP gradients provide a cleaner, more binary trigger than messy protease cleavage to unlock lethal payloads. Upside is tightly capped by platform execution risk: if in vivo assembly kinetics dilute potency or fail to show clean non-human primate biodistribution, this gets dismissed as an over-engineered masking feature.
Source: SEC EDGAR Form D filing